Skip to content


  • Poster presentation
  • Open Access

PReS-FINAL-2012: Introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 3,
  • 1,
  • 4,
  • 1 and
  • 1
Pediatric Rheumatology201311 (Suppl 2) :P25

  • Published:


  • Clinical Care
  • Dermatomyositis
  • Pediatric Rheumatology
  • Illness Outcome
  • Juvenile Dermatomyositis


In recent years, there has been an increasing interest in parent/child-reported outcomes (pcros) in pediatric rheumatology practice. Incorporation of these measures in patient assessment is deemed important as they reflect the parents' and children's perception of the disease course and the effectiveness of therapeutic interventions. Although several measures of single pcros have been developed, to date a clinical measure that groups all pcros used in the assessment of children with juvenile dermatomyositis (JDM) does not exist. Such measure would provide a physician with a thorough and systematic overview of the patient status to be scanned at the start of the visit. This would facilitate focus on matters that require attention, leading to more efficient and effective clinical care.


To develop and test a new multidimensional questionnaire incorporating all main pcros to be used in the assessment of children with JDM in standard clinical care.


The Juvenile Dermatomyositis Multidimensional Assessment Report (JDMAR) includes 15 parent/child-centered measures that assess well-being, pain, functional status, health-related quality of life, fatigue, disease activity, disease status and course, disease manifestations, side effects of medications, therapeutic compliance, problems at school, and satisfaction with illness outcome. The JDMAR is proposed for use as both proxy-report and patient self-report, with the suggested age range of 7-18 years for use as self-report.


A total of 107 consecutive JDM patients (44 male, 63 female) seen in 4 pediatric rheumatology centers (2 in Italy, 1 in UK and 1 in Croatia) were included in the study. Median disease duration was 3,1 years (IQR:1,0-5,8) and median age at visit was 10 years (IQR:6,4-13,6). All parents and children reported that the questionnaire was simple and easy to understand. Completion and scoring appeared to be quick, requiring 5-10 minutes. The proportion of parents who reported normal scores on the various JDMAR scales are summarized in the table.

Table 1

JDMAR assessments On a 10-cm VAS

Pts assessed

No. Positive (%)

Others JDMAR assessments

Pts assessed

No. Positive (%)

Normal well-being


39 (39.8)

Normal functional ability


53 (54.6)

No pain


52 (53.6)

Normal HRQL - Total score


27 (28.7)

No fatigue


24 (32.9)



50 (54.3)

No disease activity


31 (46.3)

Satisfied with illness outcome


66 (71.0)


Development of the JDMAR provides a promising approach to quantitative measurement in standard pediatric rheumatology care. Availability of this new instrument may foster regular use of parent/patient questionnaires in routine practice and contribute to improved quality of care of children with JDMAR.

Disclosure of interest

None declared.

Authors’ Affiliations

pediatria II, IRCCS G. GASLINI, Genova, Italy
Rheumatology, Great Ormond Street hospital for Children, London, UK
Pediatrics, University Hospital, Zagreb, Croatia
Pediatria, Azienda Ospedaliera Card, Panico, Tricase (LE), Italy


© Varnier et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.